Cormorant Asset Management, LP Cogent Biosciences, Inc. Transaction History

Cormorant Asset Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$9.85 - $13.24 $2.96 Million - $3.97 Million	300,000 Added 42.86%	1,000,000 $11.8 Million
Q1 2023 May 15, 2023	SELL	$10.04 - $15.5 $2.01 Million - $3.1 Million	-200,000 Reduced 22.22%	700,000 $7.55 Million
Q4 2022 Feb 14, 2023	SELL	$10.65 - $14.84 $5.86 Million - $8.16 Million	-550,000 Reduced 37.93%	900,000 $10.4 Million
Q3 2022 Nov 14, 2022	BUY	$9.39 - $16.99 $6.57 Million - $11.9 Million	700,000 Added 93.33%	1,450,000 $21.6 Million
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $2.94 Million - $7.3 Million	750,000 New	750,000 $6.77 Million

170

113M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $585M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.